Introduction
The transforming growth factors-beta (TGF-bs) are a family of multifunctional polypeptides that play pivotal roles in the control of cell proliferation, dierentiation, extracellular matrix deposition, and immunoregulation Roberts and Sporn, 1993; Moses et al., 1990) . TGF-b exerts these cellular eects through a heteromeric complex of the type I (TbR-I) and type II (TbR-II) TGF-b receptors, each containing serine/threonine kinase domains Yamashita et al., 1994) . TbR-II, a constitutively active kinase, binds directly to TGF-bs. Upon ligand binding, TbR-II recruits and phosphorylates TbR-I, thus inducing TbR-I kinase activity. However, little is known regarding the regulation of cytoplasmic components that are rapidly activated or inactivated after receptor interaction with TGF-b ligand.
Protein tyrosine kinase of the Src family is a membrane-anchored nonreceptor kinase with unique N-terminal and Src homology (SH2 and SH3) domains. It plays an essential role in various signal transduction processes that contribute to cell growth and dierentiation (Superti-Furuga and Courtneidge, 1995) . Src kinase activity is increased in various carcinoma tissues and cell lines, suggesting that it is involved in carcinogenesis (Cartwright et al., 1989 (Cartwright et al., , 1994 Kumble et al., 1997; Rosen et al., 1986; Bolen et al., 1987) . DNA synthesis induced by some growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and colony stimulating growth factor 1 (CSF-1) requires Src family protein tyrosine kinase (Roche et al., 1995a,b; Barone and Courtneidge, 1995) . G-protein coupled receptors also activate Src kinase upon ligand binding Schieer et al., 1995; Luttrell et al., 1996) . Moreover, Src tyrosine kinase is important in signal cross-talk between G-protein coupled receptors and tyrosine kinase receptors such as EGF, PDGF, and insulin-like growth factor-1 (IGF-1) receptors (Linseman et al., 1995; Rao et al., 1995; Daub et al., 1996) .
The potential role of protein kinase in TGF-b signaling has been considered since the phosphorylation state of many proteins change rapidly after TGF-b treatment and certain kinase inhibitors as well as phosphatase inhibitors can alter TGF-b signaling (Gruppuso et al., 1991; Ohtsuki and Massague, 1992) . Additionally, TGF-b aects the Ras/mitogenactivated protein kinase (MAPK) pathway in various cells (Filmus and Buick, 1992; Howe et al., 1993; Hartsough and Mulder, 1995) . TGF-b has been reported to inhibit EGF-and serum-induced Rasactivation (Howe et al., 1993) . These ®ndings suggest a possible cross-talk between growth factor receptors and TGF-b.
To determine whether Src kinase is involved in the TGF-b signaling pathway, we examined the eects of TGF-b1, a prototype of the TGF-b family, on Src kinase activity in the rat ®broblast cell line 3Y1 as well as in v-Src transformed 3Y1 cells (SR-3Y1). We also investigated the signal cross-talk between PDGF and TGF-b1 in these cells.
Results

Eect of TGF-b1 on cell proliferation
The eect of TGF-b1 on cell growth was assayed by [ tion was not signi®cantly inhibited by TGF-b1 in 3Y1 cells. In contrast, in SR-3Y1 cells which were  transformed with Rous sarcoma virus expressing the  v-Src  kinase,  TGF-b1  signi®cantly  inhibited  [   3   H ]thymidine incorporation with a maximal eect at 2 ng/mL (Figure 1) .
MAPK is serine/threonine protein kinase that is rapidly activated in response to mitogenic stimuli, and implicated in cell proliferation (Leevers and Marshall, 1992) . We examined the eect of TGF-b1 on MAPK activity by measuring [ 32 P] incorporation into myelin basic protein (MBP) in SDS-polyacrylamide gel. In SR-3Y1 cells, TGF-b1 decreased p42/p44 MAPK activity to 65% of pre-treatment level, whereas it did not aect MAPK activity in 3Y1 cells (Figure 1) .
A cross-linking study using [
125 I]TGF-b1 demonstrated that the expression of the type I, type II, and type III TGF-b receptors was similar in the two cell lines (data not shown).
Eect of TGF-b1 on Src protein kinase activity
The basal levels of Src protein kinase activity were about 13-fold higher in SR-3Y1 than in 3Y1 (486+31 c.p.m./mg protein vs 38+1, mean+s.e.m.). TGF-b1 aected Src kinase activity dierently in the two cell lines. In 3Y1 cells, TGF-b1 did not signi®cantly alter Src kinase activity. In contrast, in SR-3Y1 cells, TGF-b1 reduced Src kinase activity in a dose-dependent manner. 1 ng/mL TGF-b1 reduced Src kinase activity by approximately 65% (Figure 2 ).
Eect of TGF-b1 on cellular Src protein levels
To investigate how TGF-b1 altered Src kinase activity, we examined cellular Src levels by immunoblotting with an anti-Src monoclonal antibody, GD11, which recognizes a region between amino acid residues 82 ± 169 (Parsons et al., 1984) , or by using an anti-Src polyclonal antibody which recognizes amino acid a b residues 3 ± 18. Similar results were obtained with these two antibodies. Cellular Src protein levels were about three times higher in SR-3Y1 cells than in 3Y1 cells. The speci®c activity of cellular Src kinase was about four times higher in SR-3Y1 cells than in 3Y1 cells. Consistent with the observed alterations in cellular Src kinase activities, Src protein levels were not markedly aected by TGF-b1 treatment in 3Y1 cells, but were reduced by about 60% in SR-3Y1 cells in the presence of 1 ng/mL TGF-b1 (Figure 3 ). To con®rm that the equal amount of protein was loaded in each lane, the membrane was stained with India-ink. In both cell lines, speci®c activities of cellular Src kinase were not signi®cantly altered by TGF-b1 treatment. To con®rm that all of the Src protein in the cell was released into the RIPA extraction buer, the insoluble faction was further treated with RIPA supplemented with 1% SDS for 1 h at 48C and immunoblotted with an anti-Src antibody. Src was not detected in the RIPA-insoluble fraction, indicating complete recovery of Src in the RIPA buer (data not shown).
In SR-3Y1 cells, down-regulation of the cellular Src protein level was observed relatively quickly following TGF-b1 treatment. Namely, TGF-b1 decreased Src abundance by 60% at 15 min and 40% at 60 min ( Figure 3) .
Addition of cycloheximide, which disrupts protein synthesis, did not alter the eect of TGF-b1 on Src protein abundance in both cell lines (data not shown), suggesting decreased protein synthesis may not be the cause of v-Src down-regulation in TGF-b1-treated SR-3Y1 cells. 
Regulation of Src turnover by TGF-b1
We next examined the eect of TGF-b1 on Src protein turnover by metabolic labeling. Cells were labeled for 2 h with [ 35 S]methionine/cysteine and then chased for 2 h. Thereafter, the cells were incubated with 10 71 ng/ mL of TGF-b1 for 0 ± 2 h. In SR-3Y1, 35 S-labeled Src was markedly lower in TGF-b1-treated cells compared with untreated cells at 1 h and 2 h after treatment (Figure 4 ). This suggests that TGF-b1 markedly accelerated the degradation of v-Src in SR-3Y1 cells. In contrast, in 3Y1 cells, c-Src turnover was relatively slow and was not signi®cantly altered by TGF-b1 treatment.
Eect of TGF-b1 on activated Src
The fact that TGF-b1 markedly decreased v-Src abundance while it did not aect c-Src levels suggested the possibility that a conformational dierence between c-Src and v-Src may be responsible for the susceptibility to TGF-b1-induced protein degradation. c-Src activity is down-regulated by phosphorylation of Tyr-527 by c-terminal of Src kinase, Csk (Superti-Furuga and Courtneidge, 1995; Nada et al., 1991; Cooper and Howell, 1993) . The inactive state of c-Src is achieved through intramolecular interactions involving the phosphorylated tail tyrosine, SH2, and SH3 domain (Superti-Furuga and Courtneidge, 1995; Nada et al., 1991; Cooper and Howell, 1993; Moare® et al., 1997) . v-Src, in contrast, lacks the regulatory tyrosine phosphorylation site, and is always in an unfolded, active state. Receptor stimulation by growth factors, such as EGF or PDGF, abolishes these intramolecular interactions, resulting in a conformational change from the repressed to the active state (Leschleider et al., 1993; Peng and Cartwright, 1995) . Thus, we hypothesized that activation of c-Src might increase its susceptibility to TGF-b1-induced degradation as v-Src. To test this hypothesis, 3Y1 cells were treated with 10 ng/mL of PDGF-BB to activate c-Src. When co-incubated with PDGF-BB, TGF-b1 signi®cantly decreased c-Src abundance in 3Y1 cells, while PDGF-BB itself did not aect Src protein abundance ( Figure  5 ).
35
S-metabolic labeling indicated that the degradation of c-Src in 3Y1 cells was markedly increased when the cells were co-incubated with PDGF-BB and TGFb1 ( Figure 5 ).
Src constructs lacking the SH3 domain (SrcDSH3) are also in an unfolded, active state (Superti-Furuga et al., 1993; Moare® et al., 1997) . When 3Y1 cells expressing SrcDSH3 were treated with TGF-b1, the level of SrcDSH3 was signi®cantly decreased in a dosedependent manner up to 1 ng/mL ( Figure 6 ).
To clarify whether this TGF-b1-induced degradation was Src kinase speci®c, we also examined the eects of TGF-b1 on Fyn kinase, another member of Src kinase family, and PDGF-b receptor tyrosine kinase in PDGF-treated 3Y1 cells. The expression of Fyn was markedly scant compared with Src in 3Y1 cells, and we could not recognize signi®cant change in Fyn protein abundance (data not shown). The abundance of PDGF-b receptor was not signi®cantly aected by TGF-b1 treatment either (data not shown).
Eects of protease inhibitors on TGF-b1-induced Src degradation
We employed a series of protease inhibitors to determine whether some class of protease is involved in TGF-b1-induced degradation of activated Src 
Src ∆SH3 #9 Src ∆SH3 #15 SR-3Y1 Figure 6 Eect of TGF-b1 on Src lacking the SH3 domain. Two clones of 3Y1 cells stably transfected with Src lacking the SH3 domain (SrcDSH3 #9 and #15) were treated with various concentrations of TGF-b1 for 15 min. Cell lysates were resolved by SDS ± PAGE and SrcDSH3 protein was identi®ed by immunoblotting using anti-Src polyclonal antibody. Cell lysates of SR-3Y1 cells were also electrophoresed as a control
The decrease of v-Src abundance in SR-3Y1 cells treated with TGF-b1 was not inhibited by protease inhibitors E-64, aprotinin, and leupeptin. However, the decrease of v-Src in TGF-b1-treated SR-3Y1 cells was prevented almost completely by tosyl-L-phenylalanine chloromethyl ketone (TPCK), PMSF, pepstatin, and partially prevented by 3,4-dichloroisocumarin (DCI) (Figure 7 ).
Discussion
Src tyrosine kinase plays essential roles in the signaling pathways of various cytokine receptors, such as EGF, PDGF, CSF-1, and G-protein coupled receptors. Moreover, Src tyrosine kinase is important in signal cross-talk between these receptors. A possible crosstalk between growth factors and TGF-b has been suggested, although little is known regarding the regulation of cytoplasmic components by TGF-b. To determine whether Src kinase is also involved in TGF-b signaling, we examined the eects of TGF-b1 on c-Src and v-Src in rat ®broblast cell lines 3Y1 and v-Src transformed 3Y1, respectively. TGF-b1 decreased MAPK activation and inhibited growth in SR-3Y1 cells, while it did not aect the growth of the parental 3Y1 cells. In SR-3Y1 cells, TGF-b1 signi®cantly decreased v-Src protein kinase activity in accordance with inhibition of MAPK activity. In contrast, c-Src kinase activity was not altered by TGF-b1 treatment in 3Y1 cells. v-Src protein levels in SR-3Y1 cells were also decreased by TGF-b1 without signi®cant change in speci®c activities, suggesting that TGF-b1-induced down-regulation of Src kinase activity in SR-3Y1 cells is due to a decrease in its protein level. This decrease of v-Src abundance was observed at a relatively short period, 5 ± 15 min after TGF-b1 treatment. Metabolic labeling indicated that TGF-b1 accelerated v-Src degradation in SR-3Y1 cells, whereas it did not aect c-Src turnover in 3Y1 cells. These results indicate that the decrease in v-Src levels by TGF-b1 occurs via an accelerated degradation.
Cross-linking studies demonstrated that the expression of the type I, type II, and type III TGF-b receptors was similar between the two cell lines. This suggests that the postreceptor mechanism may be responsible for the dierence between the regulation of c-Src and v-Src in these two cell lines. The repressed state of c-Src is achieved through intramolecular interactions involving the phosphorylated tail, SH2, and SH3 domain. v-Src lacks the regulatory tyrosine phosphorylation site, and is always in unfolded, active state. Receptors stimulation by growth factor, such as EGF or PDGF (Leschleider et al., 1993; Peng and Cartwright, 1995) , or deletion of Src SH2/SH3 domains (Superti-Furuga et al., 1993; Moare® et al., 1997) abolishes these intramolecular interactions, resulting in a conformational change from the repressed to the active state.
In this study, when c-Src was activated by PDGF-BB, its degradation in 3Y1 cells was induced by TGF-b1 in a manner similar to v-Src in SR-3Y1. The level of a mutant c-Src construct lacking the SH3 domain, SrcDSH3, was also decreased by TGF-b1 treatment. These ®ndings suggest that TGF-b1 speci®cally induced the degradation of active, unfolded Src, as observed following PDGF-stimulation of c-Src, or in cells harboring v-Src or SrcDSH3. Thus, the conformational change from the folded, repressed state to the unfolded, activated state likely induce a susceptibility to TGF-b1-induced degradation.
There is increasing evidence indicating intracellular signal cross-talk between various cytokine receptors. It is of interest that TGF-b1 speci®cally induced the degradation of activated Src kinases, since Src activation plays essential roles in mitogenic signaling. It has been reported that TGF-b1 inhibited EGF-or serum-induced Ras-activation (Howe et al., 1993) . TGF-b1 may negatively control the mitogenic signal transduction of various growth factors by accelerating the degradation of active Src proteins. Recently, it has been reported that opposing signaling pathways of bone morphogenetic proteins, a member of the TGF-b superfamily, and EGF converge on the TGF-b family mediator Smad 1 (Kretzschmar et al., 1997) . Degradation of activated Src by TGF-b1 may be another novel mechanism of signal cross-talk between growth factors and TGF-bs. Figure 7 Eect of protease inhibitors on TGF-b1-induced degradation of v-Src. SR-3Y1 cells were exposed to the following
(100 mmol/L), and pepstatin (3.6 mmol/L) for 30 min before exposure to 10 71 ng/mL of TGF-b1 for 15 min. Cell lysates were resolved by SDS ± PAGE and Src protein was identi®ed by immunoblotting
It has been reported that the activities of Src family kinase, Src and Lyn, were altered by TGF-b1 treatment in a human prostatic carcinoma cell line . The existence of a Src family kinasespeci®c degradation regulated by TGF-b has been suggested. We have also found that activated Src kinase in a human hepatoma cell line, HepG2 cells, was decreased by TGF-b1 treatment (Fukuda et al.,  submitted) . Recently, it has been suggested that selective and rapid degradation of proteins plays an important role in many biological processes including signal transduction. For example, interleukin-1b-converting enzyme-like protease cleaves DNA-dependent protein kinase, inducing apoptosis (Song et al., 1996a, b) . lkB is also targeted by phosphorylation and ubiquitination for proteolytic destruction upon signaling (Coux et al., 1996) . Ligand-induced ubiquitination and degradation of the PDGF-b receptor plays a negative regulatory role in its mitogenic signaling (Mori et al., 1993 (Mori et al., , 1995 . In this study, the decrease of v-Src abundance in SR-3Y1 cells treated with TGFb1 was prevented by protease inhibitors such as TPCK, PMSF, pepstatin, and DCI. It is possible that TGF-b1 controls the activity of a protease that induces cleavage of activated Src family members, although we have not found any evidence suggesting the induction of proteolytic products. Further studies are necessary to clarify the regulation of Src kinase by TGF-b.
Src activity is increased in various malignant and premalignant tissues and cell lines, although the mechanism regulating this enhanced activity remains unclear. Loss of sensitivity to TGF-bs has also been observed in the progression of carcinogenesis (Kiso et al., 1994; Markowitz et al., 1995; Inagaki et al., 1993; Wang et al., 1996; Park et al., 1994; Oshikawa et al., 1996; Knaus et al., 1996) . It may be possible that negative control of Src kinase by TGF-bs is impaired in these tissues or cell lines, inducing Src up-regulation. Further studies are necessary to clarify the relationship between Src up-regulation and TGF-b resistance in carcinogenesis.
In conclusion, we have demonstrated that TGF-b1 speci®cally induced the degradation of activated Src kinases; v-Src, PDGF-stimulated c-Src, and Src lacking the SH3 domain in rat ®broblasts. This induction may represent a novel cross-talk between growth factors and TGF-b signaling.
Materials and methods
Materials
Human recombinant TGF-b1 was purchased from Nacalai Tesque Inc. (Kyoto, Japan). Human recombinant PDGF-BB was purchased from GIBCO BRL (Gaithersburg, MD). Mouse monoclonal antibodies to phosphotyrosine (4G10) and pp60 src (GD11) were purchased from Upstate Biotechnology Inc. (Lake Placid, NY). Rabbit polyclonal antibody to pp60 src was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Peroxidase-conjugated rabbit anti-mouse and swine anti-rabbit immunoglobulins were purchased from Dako Japan (Tokyo, Japan). Protease inhibitors were purchased from Boehringer Mannheim (Indianapolis, IN) . Protein G-Sepharose, phosphatase inhibitors, and myelin basic protein (MBP) were purchased from Sigma (St. Louis, MO). An Src kinase assay kit was purchased from Upstate Biotechnology Inc. Fetal calf serum (FCS) was purchased from Irvine Scienti®c (Santa Ana, CA). [
3 H]thymidine (37 MBq/mL), [g-32 P]ATP (370 MBq/mL), and 35 S-pro mix (530 MBq/mL) were purchased from Amersham Japan (Tokyo, Japan).
Cell culture
The rat 3Y1 ®broblast cell line and Rous sarcoma virustransformed 3Y1 (SR-3Y1) cells (Kawai, 1980; Park et al., 1992) were maintained in Dulbecco's modi®ed Eagle's minimal essential medium (DMEM) with 10% FCS, 100 u/mL penicillin, and 100 mg/mL streptomycin at 378C in 5% CO 2 .
3Y1 cells were transfected with Src constructs lacking the SH3 domain (SrcDSH3) (Superti-Furuga et al., 1993; Erpel et al., 1996) by liposome-mediated method using Lipofectamine (GIBCO). pRc/CMV plasmid (Invitrogen, San Diego, CA) was co-transfected to supply G418 (GIBCO) resistance. Transfected cells were selected by addition of 800 mg/mL G418 to the culture medium. The medium was replaced every 2 ± 3 days until foci arose. Colonies were picked and expanded, and the expression of dierent Src alleles was con®rmed by immunoblotting.
Cell proliferation assay
Eects of TGF-b1 on cell proliferation were assessed by [ 3 H]thymidine incorporation. 6610 3 cells seeded in 96-well plates were incubated with various concentrations of TGFb1 in DMEM/0.1% FCS. Twenty-hours after the addition of TGF-b1, the cells were pulse-labeled with [ 3 H]thymidine (37 kBq/well) for 4 h. Incorporated [ 3 H]thymidine was counted using a beta plate system (Pharmacia LKB, Uppsala, Sweden).
MAPK activity assay
MAPKs activity was examined by measuring [ 32 P] incorporation into MBP in SDS-polyacrylamide gel as previously described (Hartsough and Mulder, 1995) . In brief, cell lysates were electrophoresed on an SDSpolyacrylamide gel containing 0.5 mg/mL of MBP. SDS was then removed from the gel and the enzyme was renatured. Phosphorylation of MBP was carried out by incubation of the gel with kinase buer containing 925 kBq of [g-32 P]ATP. After incubation, the gel was washed in 5% trichloroacetic acid containing 1%Na 4 P 2 O 7 , dried, and subjected to autoradiography. The signal intensity of [ 32 P] incorporated into MBP was determined by densitometric analysis using Scanning Imager (Molecular Dynamics, Sunnyvale, CA).
Immunoprecipitation and Western blotting
After treatment with TGF-b1, subcon¯uent cells were washed twice with ice-cold PBS and lysed in a modi®ed RIPA buer containing 150 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.5, 1% NP-40, 0.25% sodium deoxycholate, phosphatase inhibitors (100 mmol/L Na 3 VO 4 , 10 mmol/L Na 4 P 2 O 7 , and 10 mmol/L NaF), and protease inhibitors (1 mmol/L PMSF, 2 mmol/L EGTA, 50 mg/mL leupeptin, 100 U/mL aprotinin, and 10 mg/mL a 2 macroglobulin). The insoluble material was removed by centrifugation, and the protein contents of the supernatants were measured using a Bio-Rad protein assay kit (Hercules, CA). The supernatants were immunoprecipitated with the appropriate antibody and protein G-Sepharose for 2 h at 48C. After immunoprecipitation, the samples were washed four times with lysis buer, resuspended in SDS sample buer (25 mmol/L Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, and 0.05% bromophenol blue), and heated to 908C for 3 min. Immunoprecipitated proteins were separated on an SDS-gel and transferred to polyvinylidene di¯uoride membranes (Immobilone PVDF, Millipore, Bedford, MA). The membranes were incubated with the appropriate primary antibodies, followed by peroxidase-conjugated secondary antibodies. Proteins were visualized bȳ uorography using an enhanced chemiluminescence system (Amersham). The signal intensity of each band was quantitated by densitometric analysis.
In vitro Src kinase activity assay Src kinase activity was assayed using an Src kinase assay kit according to the manufacturer's protocol. Brie¯y, mixtures of anti-Src immunoprecipitates from 100 mg of cell protein, 1 mg of Src substrate peptide (Cdc2 p34 amino acid residues 6 ± 20: KVEKIGEGTYGVVYK), and assay dilution buer (100 mmol/L Tris-HCl, pH 7.2, 125 mmol/L MgCl 2 , 100 mmol/L MnCl 2 , 2 mmol/L EGTA, 250 mmol/L Na 3 VO 4 , 2 mmol/L dithiothreitol, and 500 mmol/L ATP) containing [g-32 P]ATP (37 kBq) were incubated at 308C for 10 min. The reaction was stopped by adding 20% perchloric acid, and the mixture was pipetted onto p81 phosphocellulose paper. After washing three times with 0.75% phosphoric acid, the bound radioactivity was quantitated in a liquid scintillation counter.
Metabolic labeling of Src protein
To examine the turnover of Src, metabolic labeling of Src protein with [
35 S]methionine and cysteine was performed. 2610 5 cells seeded in 6-well plates were labeled with 3.75 MBq/mL [ 35 S]-pro mix in methionine/cysteine-free DMEM (GIBCO) supplemented with 10% FCS which had been dialyzed for 2 h. Cells were washed with PBS and the medium was changed to methionine/cysteine-plus DMEM/10% FCS and incubated for 2 h. Cells were then incubated with or without 10 71 ng/mL TGF-b1, lysed, and immunoprecipitated with an anti-Src antibody. Immunoprecipitated proteins were separated by SDS-PAGE and subjected to¯uorography.
Abbreviations TGF-b, transforming growth factor-b; TbRI, transforming growth factor-b type I receptor; TbRII, transforming growth factor-b type II receptor; SH, Src homology; SrcDSH3, Src constructs lacking the SH3 domain; MAPK, mitogen-activated protein kinase; DMEM, Dulbecco's modi®ed Eagle's minimal essential medium; FCS, fetal calf serum; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; CSF, colony stimulating growth factor; IGF-1, insulin-like growth factor-1.
